OVERVIEW OF DENGUE AND DENGVAXIA®—OPTIMISING THE USE OF DENGVAXIA®
- Author:
Leong Hoe NAM
1
Author Information
- Publication Type:Journal article
- Keywords: Dengvaxia®; Severe Dengue; Hospitalised Dengue; Benefit–Risk Ratio; Serostatus.
- From:The Singapore Family Physician 2018;44(2):36-39
- CountrySingapore
- Language:English
- Abstract: Dengue is the most rapidly spreading mosquito-borneviral disease in the world, associated with high morbidityand mortality. It is caused by the transmission of thedengue virus (DENV) through the bite of the infectedmosquito vector, Aedes aegypti. There are 4 serotypes ofDENV (1–4), and all of them circulate in Singapore.Pre-adolescents and young adults are at the highest riskof dengue in this region. In Singapore, the dengue vaccineis approved for the prevention of dengue caused by DENV1–4 in individuals aged 12–45 years living in endemic areas.The vaccine is effective in reducing symptomatic, severeand hospitalised dengue, with clear benefits inseropositive individuals.
